A Study for Patients With Type 2 Diabetes
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 289 participants.
Also called NCT01027871
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 289 participants
- Sponsor
- Registry
-
NCT01027871
-
- Other papers using this trial's data
- A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes
- Lower glucose variability and hypoglycemia measured by continuous glucose monitoring with novel long-acting insulin LY2605541 versus insulin glargine
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Hungary, Poland, Puerto Rico, Romania, Russia, Spain
- Registry status
- Completed
Technical summary
Registry record NCT01027871. Randomized; no masking; primary purpose treatment. Start 2010-01 (registry gives no type); primary completion 2010-12 (actual). Results posted on 2018-06-08.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study for Patients With Type 2 Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- LY2605541
- Intervention (Drug)
- insulin glargine
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01027871- Content hash
c6945902b8527cfb168652d5a6b9b60f791fd081b81c775945aff5073f0dd994